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The defining feature of the mycobacterial outer membrane (OM) is
the presence of mycolic acids (MAs), which, in part, render the
bilayer extremely hydrophobic and impermeable to external insults,
including many antibiotics. Although the biosynthetic pathway of
MAs is well studied, the mechanism(s) by which these lipids are
transported across the cell envelope is(are) much less known.
Mycobacterial membrane protein Large 3 (MmpL3), an essential
inner membrane (IM) protein, is implicated in MA transport, but its
exact function has not been elucidated. It is believed to be the
cellular target of several antimycobacterial compounds; however,
evidence for direct inhibition of MmpL3 activity is also lacking.
Here, we establish that MmpL3 is the MA flippase at the IM of
mycobacteria and is the molecular target of BM212, a 1,5-diary-
lpyrrole compound. We develop assays that selectively access
mycolates on the surface of Mycobacterium smegmatis sphero-
plasts, allowing us to monitor flipping of MAs across the IM. Using
these assays, we establish the mechanism of action of BM212 as a
potent MmpL3 inhibitor, and use it as a molecular probe to dem-
onstrate the requirement for functional MmpL3 in the transport of
MAs across the IM. Finally, we show that BM212 bindsMmpL3 directly
and inhibits its activity. Our work provides fundamental insights into
OM biogenesis and MA transport in mycobacteria. Furthermore, our
assays serve as an important platform for accelerating the validation
of small molecules that target MmpL3, and their development as
future antituberculosis drugs.
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The outer membrane (OM) of Mycobacterium tuberculosis, thecausative agent of tuberculosis (TB), is distinctively charac-
terized by the abundance of mycolic acids (MAs), C60–C90 long-
chain, branched fatty acids packed together to produce a bilayer
with markedly reduced fluidity and permeability (1). These MAs
come in the forms of trehalose monomycolates (TMMs), treha-
lose dimycolates (TDMs), and mycolates covalently attached to
arabinogalactan (AG) polysaccharides, which are, in turn, linked
to the peptidoglycan and collectively known as the mAGP com-
plex (Fig. 1A). MAs are synthesized at the inner membrane (IM)
as TMMs via a highly conserved and well-characterized pathway
(2), which is the target of the first-line anti-TB drug isoniazid (3).
How MAs are transported across the cell envelope and assembled
into the OM, however, is less well understood; proteins mediating
TMM flipping across the IM and transit across the periplasm have
not been identified and/or characterized (Fig. 1A). At the OM, the
Ag85 complex transfers a mycolate chain from one TMM mole-
cule to another to form TDM, or to the AG polysaccharides to
form the mAGP complex (4). Tethering the OM to the cell wall
via the AG polysaccharides further rigidifies the membrane,
making it extremely impermeable to a wide range of compounds,
including many antibiotics (1). The OM, and hence MAs, are
essential for mycobacterial growth.
Recently, a conserved essential IM protein, Mycobacterial
membrane protein Large 3 (MmpL3), has been implicated in MA
transport. Depletion of MmpL3 in Mycobacterium smegmatis re-
sults in accumulation of TMMs and reduced formation of TDMs
and AG-linked mycolates (5, 6), suggesting an impairment in
TMM transport to the OM. Consistent with this finding, MmpL3,
like other MmpL proteins, belongs to the resistance, nodulation,
and cell division (RND) protein superfamily, and is believed to be
a proton motive force (pmf)-dependent transporter (7). Based on
its cellular localization, MmpL3 is likely involved in TMM flipping
across the IM, TMM release from the IM into the periplasm, or
both (Fig. 1A). However, its exact role has not been clearly de-
fined, due largely to the lack of functional assays for its putative
transport activity. Treatment of mycobacteria with a few struc-
turally distinct small-molecule scaffolds, including ethylenedi-
amines (e.g., SQ109) (8), 1,5-diarylpyrroles (e.g., BM212) (9, 10),
adamantyl ureas (e.g., AU1235) (5), and others (11–15), results in
similar changes in mycolate species as in MmpL3 depletion. These
compounds inhibit growth and select for resistance mutations in
mmpL3; however, there is limited evidence that they are direct
MmpL3 inhibitors. The lack of activity assays for MmpL3 made it
impossible to test the proposed mechanism of action of these
putative inhibitors.
Here, we report that MmpL3 is the TMM flippase at the IM.
Using a spheroplast model, we developed assays to monitor IM
topology of TMM. We found that 1,5-diarylpyrrole BM212 in-
hibits TMM flipping across the IM in wild-type spheroplasts.
Furthermore, we showed that specific MmpL3 variants confer
resistance against this inhibition, indicating that MmpL3 is re-
quired for flipping TMM across the IM. Finally, we demon-
strated that BM212 binds MmpL3 in vitro in a specific manner,
and therefore directly targets MmpL3. Our work establishes lipid
transport activity of a key member of the MmpL protein family,
and highlights the importance of using small-molecule probes to
interrogate protein function. Our assays have great utility in the
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validation and development of MmpL3-targeting small mole-
cules as future anti-TB drugs.
Results
Spheroplasts Serve as a Viable System to Monitor TMM Topology. To
develop a functional assay for TMM flipping across the IM, we
sought a system where TMM topology in the IM can be moni-
tored. Mycobacterial spheroplasts are ideal for this purpose be-
cause they are largely devoid of the OM and cell wall (16), and
are bound only by the IM (17, 18), providing easy access to
molecules of interest at this membrane. Due to the loss of per-
iplasmic contents upon the formation of spheroplasts, we also
expect the transport pathway(s) for TMM to the OM to be dis-
rupted, thereby resulting in accumulation of TMM at the IM.
M. smegmatis spheroplasts were successfully generated via sequen-
tial treatment with glycine and lysozyme (SI Appendix, Fig. S1),
as previously reported (16). To examine whether MA synthesis is
intact in spheroplasts, we profiled newly synthesized lipids met-
abolically labeled with [14C]-acetate. Thin layer chromatography
(TLC) analysis of lipids extracted from whole cells revealed a few
major species whose syntheses are inhibited by isoniazid, in-
dicating that these species are mycolate-based lipids (Fig. 1B).
We assigned two of these species as TDM and TMM on the basis
of reported retention factors of these lipids on TLC plates de-
veloped under the same solvent system (19). We showed that
mycolates are still produced in M. smegmatis spheroplasts; how-
ever, the extracted lipids only contain TMM, and not TDM.
Furthermore, we can no longer detect newly synthesized mAGP in
the form of liberated mycolic acid methyl esters in these sphero-
plasts (SI Appendix, Fig. S2). These results are consistent with the
loss of Ag85 enzymes and the OM, where TDM and mAGP
syntheses occur, and also with the lack of TMM transport to any
possible remnants of the OM. Given the extreme hydropho-
bicity of mycolates, we conclude that newly synthesized TMMs
accumulate in the IM of spheroplasts, thus establishing a platform
for monitoring TMM flipping across the bilayer.
TMMs Accumulated in Spheroplasts Reside in the Outer Leaflet of
the IM. We next examined whether newly synthesized TMMs
accumulated in the inner or outer leaflet of the IM in sphero-
plasts by monitoring its accessibility to degradation by recombinant
LysB, a lipolytic enzyme. LysB is a mycobacteriophage-encoded
esterase that is specific for mycolates and plays the role of an
endolysin important for the release of phage particles from
infected cells (20, 21). Substantial amounts (∼77%) of newly
synthesized TMMs in spheroplasts are readily and specifically
hydrolyzed by purified LysB with the concomitant release of
MAs (Fig. 2A). Part of this hydrolysis can be attributed to
the background exposure of TMMs to LysB in a subset of
spheroplasts that lysed during the experiment (∼30–50% cell
lysis irrespective of the addition of LysB; Fig. 2B and SI Ap-
pendix, Fig. S3). The remaining newly synthesized TMMs that
were cut by LysB are likely accessible on the surfaces of intact
spheroplasts. We showed that an inactive LysB variant does
not result in the same effect (Fig. 2A). In addition, we dem-
onstrated that LysB does not enter intact spheroplasts (Fig.
2B), and that it does not induce additional cell lysis com-
pared with controls (Fig. 2B and SI Appendix, Fig. S3). Taken
Fig. 1. TMM biosynthesis is intact in mycobacterial
spheroplasts. (A) Schematic diagram illustrating the
processes important for MA transport across the cell
envelope. Following synthesis, TMMs must be flipped
across the IM, released from the IM, and then trans-
ported across the periplasm (presumably via a chap-
erone). MmpL3 is implicated in TMM transport at the
IM, but its exact role has not been elucidated. At the
OM, the Ag85 complex transfers the mycolate chain
from TMM to cell wall-linked AG polysaccharides or to
another TMM to form TDM. Other known lipid species
found in the OM and IM are omitted for simplicity. PL,
phospholipid. (B) TLC analysis of newly synthesized [14
C]-labeled lipids extracted from wild-type M. smeg-
matis cells (WC) and spheroplasts (SP), visualized by
phosphor imaging. Lipids were radiolabeled in the
presence or absence of isoniazid as indicated. The
developing solvent system comprises chloroform-
methanol-water (30:8:1). A mycolate-based species
that appears only in the presence of glucose is indicated with an asterisk. CL, cardiolipin; PE, phosphatidylethanolamine; PI, phosphatidylinositol;
PIM, phosphatidylinositol mannoside.
Fig. 2. Newly synthesized TMMs in mycobacterial spheroplasts are accessi-
ble to degradation by LysB, indicating that these TMMs reside in the outer
leaflet of the IM. (A) TLC analyses of newly synthesized [14C]-labeled lipids
extracted from M. smegmatis spheroplasts treated with functional or non-
functional (S82A) LysB. Lipids were resolved on TLCs developed using solvent
systems comprising either chloroform-methanol-water (30:8:1) (Left) or
hexane-diethylether-acetic acid (70:30:1) (Right), followed by phosphor im-
aging. In addition to MA, treatment with functional LysB resulted in the
release of an unidentified apolar lipid, annotated with an asterisk. TAG,
triacylglycerol. (B) α-GroEL2 and α-His immunoblot analyses of pellet and
supernatant fractions obtained from sedimentation of M. smegmatis sphe-
roplasts treated with functional or nonfunctional (S82A) LysB.
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together, these results establish that most newly synthe-
sized TMMs have been translocated across the IM in intact
spheroplasts, and therefore reside in the outer leaflet of the
membrane.
MmpL3 Is Responsible for Flipping TMM Across the IM. Several
compounds, including SQ109, BM212, and AU1235, are be-
lieved to affect MmpL3-mediated TMM transport because mu-
tations inmmpL3 confer resistance against these small molecules
Fig. 3. Antimycobacterial compounds BM212 and AU1235 reduce TMM accessibility to LysB in spheroplasts, indicating inhibition of TMM flipping across the IM.
Representative TLC analyses of [14C]-labeled lipids newly synthesized in the presence of indicated concentrations of BM212 and AU1235 (A) and SQ109 (B), and
extracted from M. smegmatis spheroplasts following treatment with or without purified LysB. The effects of pmf disruptors, carbonyl cyanide m-chlorophenyl
hydrazone (CCCP) and nigericin were also tested. At higher concentrations, these uncouplers affected lipid synthesis, consistent with the depletion of ATP. DMSO and
methanol were used to dissolve the respective compounds, and thus serve as negative controls. Equal amounts of radioactivity were spotted for each sample. The
developing solvent system comprises chloroform-methanol-water (30:8:1). (C) Graphical plot showing the effects of various compounds on the amounts of LysB-
accessible TMMs in spheroplasts. The percentage of TMMs accessible to LysB is given by the difference in TMM levels between samples with or without LysB
treatment, normalized against the level in control samples without LysB treatment. TMM levels in each sample were quantified as a fraction of total mycolates (TMM
+ MA). Average percentages and SDs from three biological replicates are plotted. The average background of TMM hydrolysis due to random cell lysis during the
experiment (∼40%) is indicated. Student’s t test: *P < 0.05 compared with the corresponding DMSO or methanol controls.
Fig. 4. Antimycobacterial compounds BM212 and AU1235 reduce surface display of 6-azido-TMMs in spheroplasts, indicating inhibition of TMM flipping
across the IM. (A) Schematic diagram illustrating the 6-azido-TMM surface display assay. Spheroplasts were incubated with 6-azido-trehalose to allow syn-
thesis of 6-azido-TMMs (22), which were subsequently labeled with alkyne-containing biotin (DIBO-biotin) via click chemistry (23). Surface-exposed biotin-
TMMs were recognized by Alexa Fluor 488-conjugated streptavidin and visualized by fluorescence microscopy. Representative bright-field and fluorescence
microscopy images are shown following DIBO-biotin/Alexa Fluor 488-streptavidin labeling of spheroplasts synthesizing TMM (B), or 6-azido-TMM in the
presence of DMSO (C), BM212 (D, twofold MIC), and AU1235 (E, twofold MIC). (Scale bars: 3 μm.) (F) Fluorescence intensity per unit area for individual
spheroplasts (n = 100) in each condition in B–E is plotted, with the medians and interquartile ranges indicated. Mann–Whitney test: ****P < 0.0001 compared
with the “no drug treatment” control.
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(5, 8, 9). Although it is not yet clear if these compounds di-
rectly inhibit MmpL3, they may be useful as probes to deter-
mine if MmpL3 is responsible for TMM flipping across the IM.
Specifically, we asked whether these small molecules are able
to inhibit TMM flipping in wild-type spheroplasts, and whether
they would become less effective in doing so in spheroplasts
expressing MmpL3 variants that confer resistance against them.
We first tested the effects of these compounds in our LysB assay
in wild-type spheroplasts. Remarkably, BM212 and AU1235 are
able to reduce LysB-mediated hydrolysis of newly synthesized
TMMs in M. smegmatis spheroplasts (Fig. 3 A and C), at concen-
trations twofold and fourfold above their reported minimal inhibitory
concentrations (MICs) (5, 9) (SI Appendix, Table S1). In contrast,
SQ109 has no effect (Fig. 3 B andC). For BM212, hydrolysis by LysB
is strongly reduced, close to the level of background attributed to
nonspecific spheroplast lysis (SI Appendix, Fig. S3). We showed
that the effects of BM212 and AU1235 are not due to direct
inhibition of LysB activity, because TMMs are still hydrolyzed in
detergent-solubilized samples (SI Appendix, Fig. S4). Instead,
significant amounts of newly synthesized TMMs are no longer
accessible to LysB in the presence of either compound in intact
spheroplasts, indicating inhibition of TMM flipping across the
IM. As an alternative method to assess TMM topology in the IM
and the effects of these drugs, we also examined the ability of
membrane-impermeable fluorophore-conjugated streptavidin to
bind to newly synthesized TMMs engineered to contain biotin
(biotin-TMMs) (Fig. 4A). Here, we metabolically labeled TMMs
with 6-azido-trehalose (22), which allowed us to attach an alkyne-
containing biotin probe covalently to TMM via the bioorthogonal
click reaction (23). In wild-type spheroplasts, biotin-TMMs can
be detected on the surface, indicating that 6-azido-TMMs have
been translocated across the IM (Fig. 4 C and F). Biotin labeling
of 6-azido-trehalose groups, and therefore detection with strep-
tavidin, was largely prevented if LysB was added (SI Appendix,
Fig. S5), confirming that we are visualizing trehalose-linked
mycolates (i.e., TMMs) at the IM in spheroplasts. We demon-
strated that both BM212 and AU1235 drastically reduce the
amounts of 6-azido-TMMs, and hence biotin-TMMs, that can be
labeled with streptavidin (Fig. 4 D–F). Again, SQ109 is not ef-
fective in this assay (SI Appendix, Fig. S6). Consistent with the
LysB accessibility assay, these results establish that BM212 and
AU1235, but not SQ109, inhibit TMM flipping across the IM.
To establish whether MmpL3 is responsible for flipping TMM
across the IM, we used specific MmpL3 variants that render
M. smegmatis cells less sensitive to BM212, and tested if TMM
flipping in spheroplasts expressing these variants would be more
Fig. 5. Mutations in MmpL3 render BM212 less effective in the inhibition of TMM flipping across the IM. Representative TLC analyses of [14C]-labeled lipids
newly synthesized in the presence of indicated concentrations of BM212 and extracted from wild-type (WT) (A), mmpL3V197M (B), and mmpL3A326T
(C) M. smegmatis spheroplasts following treatment with or without purified LysB are shown. Equal amounts of radioactivity were spotted for each sample. The
developing solvent system comprises chloroform-methanol-water (30:8:1). (D) Graphical plot showing the dose-dependent effects of BM212 on the percentage of
TMMs accessible to LysB in the respective spheroplasts (quantification as per Fig. 3). Average percentages and SDs from three biological replicates are plotted. The
average background of TMM hydrolysis due to random cell lysis during the experiment (∼40%) is indicated. Student’s t test: *P < 0.05, **P < 0.01 compared with
the corresponding DMSO controls for each respective strain. Representative bright-field and fluorescence microscopy images are shown following DIBO-biotin/
Alexa Fluor 488-streptavidin labeling of mmpL3V197M spheroplasts synthesizing TMM (E), 6-azido-TMM in the presence of DMSO (F) and 6-azido-TMM in the
presence of BM212 (G, twofold MIC). (Scale bars: 3 μm.) (H) Fluorescence intensity per unit area for individual spheroplasts (n = 100) in each condition in E–G is
plotted, with the medians and interquartile ranges indicated. Mann–Whitney test: N.S., not significant (P > 0.5 compared with the “no treatment” control).
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resistant to the effects of BM212. The growth of cells expressing
MmpL3V197M or MmpL3A326T variants is only fully inhibited in
the presence of four- to eightfold the concentration of BM212 that
inhibits wild-type growth (9) (SI Appendix, Table S1). We showed
that BM212 does not affect MmpL3 levels in wild-type sphero-
plasts (SI Appendix, Fig. S7); yet, it strongly inhibits TMM flipping
in a dose-dependent manner (Fig. 5 A and D). We further dem-
onstrated that BM212 is less effective at reducing LysB accessi-
bility to TMM in spheroplasts expressing MmpL3V197M or
MmpL3A326T variants (Fig. 5 B–D). In fact, BM212 is also unable
to inhibit the display of 6-azido-TMMs on the surface of sphero-
plasts expressing MmpL3V197M (Fig. 5 E–H). Because TMM is
only accessible on the outer leaflet of the IM in the presence of
functional MmpL3 (i.e., not inhibited by BM212), we conclude
that MmpL3 is the TMM flippase.
BM212 Binds and Directly Inhibits MmpL3 Function.MmpL3 function
is believed to require the pmf, specifically the proton gradient
(7). Consistently, we showed that proton gradient uncouplers,
such as carbonyl cyanide m-chlorophenyl hydrazone and nigericin
(Fig. 3), but not membrane potential disruptors, such as valino-
mycin-K+ (SI Appendix, Fig. S8), can inhibit LysB accessibility to
TMMs in spheroplasts. Whether BM212 inhibits TMM flipping
by directly targeting MmpL3 is not clear. Contrary to previous
reports (24), we did not observe effects on the proton gradient
(SI Appendix, Table S2) or the membrane potential (SI Appendix,
Fig. S10) in spheroplasts treated with BM212 at concentra-
tions that inhibited TMM flipping. Therefore, BM212 does not
inhibit MmpL3 via indirect effects on the pmf. To determine if
BM212 directly targets MmpL3, we examined the ability of BM212
to bind physically to purified MmpL3 (SI Appendix, Fig. S11) in
vitro. We demonstrated that [14C]-BM212 binds purified wild-type
MmpL3 in a saturable manner, with an apparent Kd of ∼66 μM (or
∼27 μg/mL) (Fig. 6A). Given that the binding assay was performed
using purified MmpL3 solubilized in detergent (as opposed to
being in a native lipid bilayer), it is highly likely that this Kd value is
overestimated; the real Kd of [
14C]-BM212 binding to MmpL3 may
thus be closer to the MIC (∼7.6 μM or 3.1 μg/mL), consistent with
a specific binding event. To corroborate this finding, we further
showed that this interaction can be competed away by excess
nonlabeled BM212 (∼100-fold above saturation binding) (Fig. 6B),
indicating that BM212 can bind to MmpL3 in a specific manner. In
fact, mutations in mmpL3 that confer resistance to BM212 mostly
cluster in a specific region when mapped onto a structural model of
MmpL3 (Fig. 6C), revealing a possible binding site. We conclude
that BM212 inhibits TMM flipping across the IM by binding
MmpL3 directly.
Discussion
How the mycobacterial OM is assembled is not well understood.
Many members of the MmpL protein family are believed to be
transporters that contribute to the assembly of various OM lipids
(25–28); however, their specific roles have not been clearly defined.
MmpL3 is the only member of this family essential for growth (5–7).
Using two independent assays that allow determination of TMM
topology in the IM of mycobacterial spheroplasts, and using putative
inhibitors as molecular probes to modulate protein function,
we have provided strong biochemical evidence that establishes
MmpL3 as the TMM flippase. Whether MmpL3 is the only pro-
tein mediating TMM flipping or whether it is also involved in
TMM release from the IM is not clear (Fig. 1A). One can posit
that a second, still unidentified, protein may be necessary for
extracting TMM from the IM and handing it to a putative chap-
erone. This scenario would be comparable to the transport of li-
poproteins across the cell envelope in gram-negative bacteria (29).
Alternatively, this step may also be mediated by MmpL3, in which
case, flipping and release of TMM might be coupled, suggesting
MmpL3 could interact with the putative chaperone. Extending
from this idea, a third scenario may be possible where TMM
flipping and release are essentially one single step in a mechanism
similar to RND efflux pumps, whereby TMM never really resides
in the outer leaflet of the IM. This latter model is, however, less
likely because we have been able to decouple these steps by ob-
serving TMM translocation across the IM in our spheroplasts,
which are effectively devoid of any putative chaperones. More-
over, despite being in the same RND protein superfamily, the
structure of MmpL3 differs substantially from canonical RND
efflux pumps (30). MmpL3 does form trimers like RND pumps
(31), but the periplasmic domains of MmpL3 are much smaller
(30) and it contains a large C-terminal cytoplasmic domain.
Therefore, MmpL3 may not export TMM via an efflux mecha-
nism. Further characterization of this system would be necessary
to tease apart these models.
TB is one of the leading causes of death by infectious disease,
and remains a major health problem worldwide (32). With the
rapid emergence of multidrug-resistant and extensive drug-
resistant TB, there is an urgent need to develop anti-TB drugs
with novel mechanisms of action. In this regard, drugs inhibiting
MmpL3, which has been shown to be an ideal target (33), would
be especially important. Although many small molecules are
thought to inhibit MmpL3, it is puzzling how molecules with
Fig. 6. BM212 binds MmpL3 in vitro in a spe-
cific manner. (A) Representative Clear Native-PAGE
analyses of purified MmpL3-His samples incubated
with increasing concentrations of [14C]-BM212, vi-
sualized separately by phosphor imaging and
Coomassie blue (CB) staining. The amount of
[14C]-BM212 bound to MmpL3 at each concentration
was quantified, normalized to the amount at maxi-
mum binding, averaged across triplicates, and
plotted. Error bars represent SDs. The data were fitted
to a “one-site–specific binding” model using nonlinear
regression (Kd = 65.5 ± 17.9 μM). (B) Clear Native-PAGE
analyses of purifiedMmpL3-His samples incubated with
a fixed concentration of [14C]-BM212, but in the pres-
ence of increasing concentrations of cold BM212. Gels
were visualized separately by phosphor imaging and CB
staining. (C) Mutations that confer resistance against
BM212 cluster on a structural model of MmpL3, sug-
gesting a possible binding site. A Phyre2 (35) structural
model for M. smegmatis MmpL3 without its C-terminal
cytoplasmic domain is shown in side (Left) and top
(Right) views. For clarity, periplasmic domains are removed from the top-view image. Residues important for passage of protons are highlighted in black. Residues
that conferred resistance against BM212 (10) when mutated in MmpL3 from M. smegmatis, Mycobacterium bovis bacillus Calmette–Guérin, and M. tuberculosis
are highlighted in red, purple and cyan, respectively.
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different molecular scaffolds may bind and target the same pro-
tein. We have now developed assays that measure the topology of
TMM in the IM of mycobacterial spheroplasts, allowing the vali-
dation of true MmpL3 inhibitors. As a start, we have established
that BM212 binds MmpL3 directly and inhibits its function. Fur-
thermore, we have shown that SQ109, a molecule that has reached
phase IIb clinical trials (Sequella), does not actually inhibit TMM
flipping. In fact, it is likely that many of these molecules do not
inhibit MmpL3 and have other targets, as has been shown for
tetrahydropyrazo[1,5-a]pyrimidine-3-carboxamides (34). Our as-
says will help to select and advance small molecules currently
under development as MmpL3-targeting drugs.
Materials and Methods
Detailed descriptions of all experimental procedures can be found in
SI Appendix.
Assessing TMM Accessibility to Degradation by Purified LysB in Spheroplasts.
M. smegmatis spheroplasts were metabolically labeled with sodium
[1-14C]-acetate for 2 h, followed by addition of purified LysB for 30 min at
37 °C. Lipids were extracted directly after the LysB treatment, analyzed by TLC,
and visualized via phosphor imaging. Where indicated, putative MmpL3 in-
hibitors were added 15 min before addition of [14C]-acetate.
6-Azido-TMM Surface Display Assay. M. smegmatis spheroplasts were meta-
bolically labeled with 6-azido-trehalose for 2 h at 37 °C to synthesize
6-azido-TMMs, which were then reacted with Click-IT Biotin DIBO alkyne to
generate biotin-TMMs. Surface-exposed biotin-TMMs were detected on
spheroplasts using Alexa Fluor 488-conjugated streptavidin and visualized by
fluorescence microscopy. Where indicated, putative MmpL3 inhibitors were
added 15 min before addition of 6-azido-trehalose and included in all
wash buffers.
BM212-MmpL3 Binding Assay. Purified MmpL3 was incubated with indicated
concentrations of [14C]-BM212 and/or cold BM212 for 30min at room temperature.
Samples were analyzed using Clear Native-PAGE, followed by phosphor imaging
and Coomassie blue staining.
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